Gerresheimer Faces Critical Financing Talks Amid Accounting Scrutiny

Pharma packager Gerresheimer battles default, a €240M impairment, and a BaFin probe. Asset sales and an SDAX exit follow a 70% stock plunge as it races to publish audited 2025 accounts.

The pharmaceutical packaging group Gerresheimer is engaged in a multi-front battle to secure its financial footing. The company is currently in technical default on its credit agreements, having failed to produce an audited annual report for 2025. As management holds urgent talks with lenders to prevent the cancellation of essential credit facilities, financial regulators are deepening their probe into the firm's accounting practices.

Regulatory Investigation Intensifies

Germany's Federal Financial Supervisory Authority (BaFin) has expanded its ongoing examination, now covering the period through May 2025. The investigation, supported by auditor Grant Thornton alongside the regular auditor KPMG, focuses on questionable bill-and-hold sales agreements and potentially misstated lease liabilities totaling €65.5 million. The new executive board has already acknowledged deliberate breaches of international accounting rules by employees. Furthermore, the conglomerate anticipates non-cash impairment charges that could reach €240 million.

Liquidity Pressures Trigger Asset Sales and Index Exit

To maintain liquidity during this precarious phase, Gerresheimer's leadership is taking severe measures. Its US subsidiary Centor is on the block, and the Chicago Heights production site is slated for closure by the end of 2026. Market uncertainty has severely impacted the company's shares. A formal removal from the SDAX index has forced index-tracking funds to divest their holdings, adding significant downward pressure on the stock. Trading at €18.90, the share price has collapsed nearly 70% over the past twelve months. Some investors, including Deka Investment, are however using the depressed valuation to establish new positions.

A Timeline for Resolution

Prospective buyers and creditors are now demanding reliable financial data. The company's published schedule outlines several key milestones for providing clarity:

• June 2026: Anticipated publication of the audited annual financial statements.
• 14 July 2026: Planned release of the half-year report.
• 15 October 2026: Third-quarter interim report.

The certified financial statements due in June represent a non-negotiable prerequisite for stabilizing the business. Only with these audited figures can the full scale of the accounting discrepancies be measured and a sustainable agreement with creditors be reached. Until that deadline, the company's annual revenue forecast of up to €2.4 billion and any potential takeover scenarios remain under strict reservation.